Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 2,562 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the sale, the chief financial officer now owns 75,557 shares of the company's stock, valued at $10,457,844.37. This represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The shares were sold at an average price of $146.04, for a total value of $115,663.68.
- On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76.
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
- On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
Natera Price Performance
Shares of NASDAQ NTRA traded down $4.84 during mid-day trading on Friday, reaching $133.87. 3,247,142 shares of the company traded hands, compared to its average volume of 1,377,854. The firm has a market cap of $18.10 billion, a PE ratio of -76.06 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The stock has a fifty day simple moving average of $156.81 and a 200-day simple moving average of $151.40.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Hedge Funds Weigh In On Natera
Several large investors have recently made changes to their positions in the business. Daiwa Securities Group Inc. bought a new stake in shares of Natera during the 3rd quarter worth $232,000. The Manufacturers Life Insurance Company boosted its position in shares of Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company's stock valued at $8,621,000 after purchasing an additional 31,649 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Natera by 5.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company's stock valued at $3,344,000 after purchasing an additional 1,263 shares during the period. Captrust Financial Advisors increased its stake in Natera by 108.7% in the 3rd quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company's stock worth $722,000 after purchasing an additional 2,963 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in Natera during the 3rd quarter worth about $238,000. Institutional investors own 99.90% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 target price for the company. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. Canaccord Genuity Group restated a "buy" rating and set a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Finally, BTIG Research reiterated a "buy" rating on shares of Natera in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $178.12.
Get Our Latest Stock Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
